| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | KALA | Common Stock | Award | $0 | +9.53K | +469.21% | $0.00 | 11.6K | Jan 4, 2023 | Direct | F1, F2 |
| transaction | KALA | Common Stock | Sale | -$1.71K | -60 | -0.52% | $28.55 | 11.5K | Jan 4, 2023 | Direct | F3, F4, F5 |
| Id | Content |
|---|---|
| F1 | Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the Reporting Person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2024, as to 1/3 of the shares underlying the RSUs on January 4, 2025 and as to the final 1/3 of shares underlying the RSUs on January 4, 2026. |
| F2 | Includes 9,827 unvested RSUs. |
| F3 | This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's performance-based restricted stock units ("RSUs") granted on January 4, 2021. |
| F4 | The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.52 to $28.79, inclusive. The Reporting Person undertakes to provide to Kala Pharmaceuticals, Inc., any security holder of Kala Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. |
| F5 | Includes 9,676 unvested RSUs. |
General Counsel, Chief Compliance Officer and Secretary